First Ever Large Scale Orthopedic Study Published in JBJS as Leading Article Approves the Change in How Patients are Treated to Prevent Deep Vein Thrombosis (DVT) After Joint Replacement
OR AKIVA, Israel, February 11, 2014 /PRNewswire/ —
A multicenter research initiated by The Shiley Center for Orthopaedic Research and Education at Scripps Clinic which is devoted to improving patient care and quality of life, approves the change in how patients are treated to prevent DVT after hip and knee replacement surgery. The study published this week as the lead article in the Journal of Bone and Joint Surgery determined that after lower extremity joint replacement surgery ActiveCare®+SFT mobile compression device was non inferior to blood thinners in preventing DVT, but without negative side effects including bleeding complications.
Orthopedic surgeon Prof. Clifford Colwell who led this research, evaluated the efficacy of ActiveCare®+SFT mobile compression device that is small and portable enough for patients to use at home, for 10 days or longer after joint replacement surgery.
“Blood thinners have long been considered the standard of care to prevent blood clots after orthopedic surgery, but they can have side effects that are concerning for many patients,” said Prof. Colwell. “Through this research we have found and established an equally effective means of accomplishing the same goal with an added layer of safety for patients.”
Ten high volume medical centers in the United States participated in a registry to collect data on the occurrence of DVT in 3,060 patients who used ActiveCare®+SFT, mobile compression device after surgery. ActiveCare®+SFT is the only device that works by delivering compressions to the leg that coordinate with a patient’s respiration rate thereby improving blood flow and reducing the risk of blood clot formation in the lower limb.
“What orthopedic surgeons are looking for is a prophylactic modality that is effective, acceptable to patients, has minimal side effects, and is cost-effective,” wrote Prof. Yates Piers in a special commentary article in JBJS February 2014 edition.
According to Rick Randall, CEO of MCS, the medical device company that develops, manufactures and markets this innovative treatment to major medical centers in the US “ActiveCare®+ is not only safer but also generates high compliance results for patients in the hospital and out of the hospital, after discharge. Moreover, it is actually cost effective to the health providers as it reduces readmission that results from DVT and complications associated with the use of blood thinners.”
ActiveCare®+SFT is the only device that fully meets the ACCP 2012 Guidelines as standalone therapy without the need of drugs to prevent DVT/PE after total joint replacement for the whole duration of treatment from hospital to home. ActiveCare® is currently used in more than 80 surgical centers across the country daily.
About MCS
MCS Medical Compression System is a medical device company that develops manufactures and markets the brand ActiveCare®, innovative non-invasive solutions for the prevention of Venous Thromboembolism (VTE). Founded in 1997, MCS is an Israeli public company, traded on the Tel Aviv Stock Exchange (TASE: MDCL). MCS Inc., the company’s subsidiary, is located in the USA.
